Last $66.36 USD
Change Today 0.00 / 0.00%
Volume 0.0
PRXL On Other Exchanges
Symbol
Exchange
NASDAQ GS
Stuttgart
As of 8:10 PM 03/5/15 All times are local (Market data is delayed by at least 15 minutes).

parexel international corp (PRXL) Snapshot

Open
$64.70
Previous Close
$64.29
Day High
$66.49
Day Low
$64.23
52 Week High
03/5/15 - $66.49
52 Week Low
04/30/14 - $41.79
Market Cap
3.6B
Average Volume 10 Days
374.2K
EPS TTM
$2.67
Shares Outstanding
54.8M
EX-Date
--
P/E TM
24.9x
Dividend
--
Dividend Yield
--
Current Stock Chart for PAREXEL INTERNATIONAL CORP (PRXL)

Related News

No related news articles were found.

parexel international corp (PRXL) Related Businessweek News

No Related Businessweek News Found

parexel international corp (PRXL) Details

PAREXEL International Corporation, a biopharmaceutical outsourcing services company, provides clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology products and services for pharmaceutical, biotechnology, and medical device industries worldwide. The company operates in three segments: Clinical Research Services (CRS), PAREXEL Consulting Services (PC), and PAREXEL Informatics (PI). The CRS segment offers clinical trials management, observational studies, patient/disease registries and post-marketing surveillance, data management and biostatistics, epidemiology and health economics/outcomes research, clinical logistics, pharmacovigilance, and clinical pharmacology, as well as related medical affairs, patient recruitment, and investigator site services. The PC segment provides technical expertise and advice in various areas, such as drug development, regulatory affairs, product pricing and reimbursement, commercialization and strategic compliance, and good manufacturing practice compliance consulting; and market development, product development, commercialization, and targeted communications services in support of product launch. The PI segment offers information technology solutions comprising ClinPhone randomization and trial supply management solutions, medical imaging services, regulatory information management solutions, platform solutions, clinical trial management system solutions, electronic data capture systems, Web-based portals, systems integration, electronic patient reported outcomes, and patient diary applications. The company was founded in 1983 and is headquartered in Waltham, Massachusetts.

15,560 Employees
Last Reported Date: 08/20/14
Founded in 1983

parexel international corp (PRXL) Top Compensated Officers

Founder, Chairman and Chief Executive Officer
Total Annual Compensation: $883.3K
President and Chief Operating Officer
Total Annual Compensation: $570.0K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $691.5K
Senior Vice President of Clinical Research Se...
Total Annual Compensation: $496.7K
Executive Vice President
Total Annual Compensation: $430.0K
Compensation as of Fiscal Year 2014.

parexel international corp (PRXL) Key Developments

PAREXEL International Corporation Reports Unaudited Consolidated Financial Results for the Second Quarter and Six Months Ended December 31, 2014; Provides Earnings Guidance for the Third Quarter of 2015; Revises Earnings Guidance for the Year 2015

PAREXEL International Corporation reported unaudited consolidated financial results for the second quarter and six months ended December 31, 2014. For the quarter, the company's total revenue was $575.045 million compared to $574.236 million in the prior year period. Income from operations was $52.784 million as compared with $46.664 million a year ago. GAAP net income for the quarter was $38.760 million, or $0.70 per diluted share, compared with GAAP net income of $28.329 million, or $0.49 per diluted share a year ago. Income before income taxes was $53.851 million compared to $42.957 million reported a year ago. Non GAAP operating income was $52.999 million compared to $47.735 million reported a year ago. Non GAAP net income was $38.361 million, or $0.69 per diluted share compared to $29.130 million or $0.51 per diluted share a year ago. Non GAAP income before income taxes was $54.203 million compared to $44.028 million reported a year ago. Capital expenditures were $11.466 million, in line with plans compared to $19.828 million reported a year ago. For the six months, the company's total revenue was $1,148.734 million compared to $1,103.3 million in the prior year period. Income from operations was $106.364 million as compared with $88.545 million a year ago. GAAP net income was $75.902 million, or $1.36 per diluted share, compared with GAAP net income of $54.283 million, or $0.95 per diluted share a year ago. Income before income taxes was $109.072 million compared to $81.873 million reported a year ago. Non GAAP operating income was $105.806 million compared to $89.696 million reported a year ago. Non GAAP net income was $74.684 million, or $1.34 per diluted share compared to $54.960 million, or $0.96 per diluted share a year ago. Non GAAP income before income taxes was $108.651 million compared to $83.024 million reported a year ago. Capital expenditures were $12.14 million compared to $14.27 million reported a year ago. Net debt came down to approximately $59 million as a result of the strong cash flow generation in the quarter, which was partially used to reduce the utilization of the company revolving credit line. Return on invested capital improved to 20.6%, driven by the improved margin expansion and limited overall capital needs in the business. For the third quarter of 2015, the company revenue will be in the range of $507 million - $521 million and GAAP EPS will be in the range of $0.62 - $0.68. For the year 2015, the company now expects revenue will be in the range of $2.040 billion - $2.070 billion, GAAP EPS will be in the range of $2.68 - $2.86 and non-GAAP EPS will be in the range of $2.65 - $2.83 against revenue range of $2.070 billion - $2.110 billion, GAAP EPS range of $2.58 - $2.77 and non-GAAP EPS range of $2.56 - $2.75 expected previously.

PAREXEL International Corporation Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 11:00 AM

PAREXEL International Corporation Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 11:00 AM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Josef H. von Rickenbach, Founder, Chairman and Chief Executive Officer.

PAREXEL International Corporation Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015

PAREXEL International Corporation Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 . Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PRXL:US $66.36 USD +2.07

PRXL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Charles River Laboratories International Inc $77.70 USD 0.00
GFK SE €35.99 EUR -0.255
ICON PLC $67.84 USD 0.00
Advisory Board Co/The $53.73 USD +0.01
WuXi PharmaTech Cayman Inc $40.96 USD +0.26
View Industry Companies
 

Industry Analysis

PRXL

Industry Average

Valuation PRXL Industry Range
Price/Earnings 24.4x
Price/Sales 1.8x
Price/Book 6.0x
Price/Cash Flow 15.3x
TEV/Sales 1.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PAREXEL INTERNATIONAL CORP, please visit www.parexel.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.